Anton Hagenbeek, MD, PhD from the University of Amsterdam, Amsterdam, Netherlands discusses how he hopes the treatment of cancer will progress in future. Prof. Hagenbeek hopes for intelligent combinations of targeted agents and a move towards personalized medicine. He further argues for conducting small Phase II trials in order to speed up the process of drug approval, meaning that drugs could become available at faster rates.
Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.

свернуть